Metabolic Core

Description

The Metabolic Core Research Kit combines SG-1 (Semaglutide, 30mg) and Cagrilintide (10mg) — replicating the clinical CagriSema combination that demonstrated superior weight loss to semaglutide alone in Phase 2/3 trials. This kit provides the primary research tool for studying complementary GLP-1 receptor and amylin receptor co-activation in metabolic research.

Kit Components

• SG-1 / Semaglutide (30mg): Long-acting GLP-1R agonist (~7-day half-life). Suppresses glucagon, potentiates insulin secretion, delays gastric emptying, and activates hypothalamic POMC neurons for appetite suppression.
• Cagrilintide (10mg): Long-acting amylin analogue (~7-day half-life). Activates AMY1/2/3 receptors in the hypothalamus and brainstem for complementary satiety signaling, independent of the GLP-1 pathway.

Research Context

The semaglutide + cagrilintide combination (CagriSema) produced approximately 15% body weight reduction vs. 8% for semaglutide alone in Phase 2 data — demonstrating the additive value of simultaneous GLP-1 and amylin receptor activation. For researchers, this kit enables investigation of this complementary dual-pathway mechanism: why do two independent satiety pathways produce more than additive effects, and what are the downstream metabolic consequences?

Common Research Applications

• GLP-1R + amylin receptor co-activation studies
• CagriSema combination mechanism research
• Complementary satiety pathway interaction investigation
• Beta cell biology and dual incretin/amylin receptor research

For Research Use Only. Not for human or veterinary use.